Overview

• The FTSE 100 medtech group will invest more than $1 billion across the UK and US over the next decade, including about $600 million in America.
• An expanded Boston R&D site is slated to be completed by the end of this year as part of the US programme.
• Around 200 roles will transfer from Convatec’s Deeside R&D centre to Manchester, with room for up to 250 staff and a phased move with no planned redundancies.
• Deeside’s manufacturing operation will continue as a cornerstone with roughly 400 jobs and some R&D retained to support production.
• The Manchester hub will be one of the company’s largest and will conduct research across advanced wound care, ostomy care, continence care and infusion care, against a backdrop of other majors shifting investment toward the US.